BiotechTube

Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + Budigalimab

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Human Immuno-deficiency Virus (HIV) Disease

Conditions

Human Immuno-deficiency Virus (HIV) Disease

Trial Timeline

Oct 12, 2023 → Sep 22, 2025

NCT ID
NCT06032546

About Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + Budigalimab

Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + Budigalimab is a phase 2 stage product being developed by AbbVie for Human Immuno-deficiency Virus (HIV) Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT06032546. Target conditions include Human Immuno-deficiency Virus (HIV) Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06032546Phase 2Terminated

Competing Products

20 competing products in Human Immuno-deficiency Virus (HIV) Disease

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
25
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
77
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
52
DolutegravirShionogiPhase 3
77
GSK1349572 + efavirenzShionogiPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
33
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
77
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
33
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
dolutegravirShionogiPhase 3
77
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
77
GSK1349572 + EfavirenzShionogiPhase 1
33
GSK1349572ShionogiPhase 1
33
GSK1349572 + PlaceboShionogiPhase 2
52
Dolutegravir + MethadoneShionogiPhase 1
33
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
77
GSK1349572 + Rifampin + RifabutinShionogiPhase 1
33
DTG + BCV + TVRShionogiPhase 1
33

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85